Radio-Pharmaceuticals Firm
Applications drive the growth of nuclear medicine. For the past several decades SPECT nuclear medicine has been without a new blockbuster application. The growing field of Theranostics, the combination of radiopharmaceuticals or other imaging agents and directed therapy, may be influenced heavily by this purchase. Novartis has the investment capability to choose and develop new radiopharmaceuticals for nuclear medicine applications and directed patient therapy. This can stimulate this market in the coming years with new products and applications growing nuclear medicine.
Click here to read more.